CA2718538A1 - Quinoline derivatives as axl kinase inhibitors - Google Patents

Quinoline derivatives as axl kinase inhibitors Download PDF

Info

Publication number
CA2718538A1
CA2718538A1 CA2718538A CA2718538A CA2718538A1 CA 2718538 A1 CA2718538 A1 CA 2718538A1 CA 2718538 A CA2718538 A CA 2718538A CA 2718538 A CA2718538 A CA 2718538A CA 2718538 A1 CA2718538 A1 CA 2718538A1
Authority
CA
Canada
Prior art keywords
yloxy
phenyl
quinolin
fluoro
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718538A
Other languages
English (en)
French (fr)
Inventor
Axel Ullrich
Pjotr Knyazev
Yixiang Zhang
Gyorgy Keri
Laszlo Orfi
Istvan Szabadkai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Publication of CA2718538A1 publication Critical patent/CA2718538A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2718538A 2008-04-16 2009-04-16 Quinoline derivatives as axl kinase inhibitors Abandoned CA2718538A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4539808P 2008-04-16 2008-04-16
US61/045,398 2008-04-16
PCT/EP2009/002798 WO2009127417A1 (en) 2008-04-16 2009-04-16 Quinoline derivatives as axl kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2718538A1 true CA2718538A1 (en) 2009-10-22

Family

ID=40999731

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718538A Abandoned CA2718538A1 (en) 2008-04-16 2009-04-16 Quinoline derivatives as axl kinase inhibitors

Country Status (12)

Country Link
US (1) US9206130B2 (cg-RX-API-DMAC7.html)
EP (1) EP2262772B8 (cg-RX-API-DMAC7.html)
JP (1) JP5746015B2 (cg-RX-API-DMAC7.html)
KR (1) KR101325237B1 (cg-RX-API-DMAC7.html)
CN (1) CN102131783A (cg-RX-API-DMAC7.html)
AU (1) AU2009237938A1 (cg-RX-API-DMAC7.html)
CA (1) CA2718538A1 (cg-RX-API-DMAC7.html)
ES (1) ES2391373T3 (cg-RX-API-DMAC7.html)
IL (1) IL208103A (cg-RX-API-DMAC7.html)
MX (1) MX2010011224A (cg-RX-API-DMAC7.html)
RU (1) RU2010146474A (cg-RX-API-DMAC7.html)
WO (1) WO2009127417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311809A1 (en) * 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
PT2780338T (pt) 2011-11-14 2017-02-17 Ignyta Inc Derivados de uracil como inibidores da quinase axl e c-met
JP6006241B2 (ja) 2012-01-31 2016-10-12 第一三共株式会社 ピリドン誘導体
CA2879542A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
CN105916506B (zh) 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
CA2922542A1 (en) * 2013-11-22 2015-05-28 University Of Kentucky Research Foundation Arylquinoline and analog compounds and use thereof to treat cancer
EP3074390B1 (en) 2013-11-27 2020-07-08 SignalChem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
WO2017146236A1 (ja) 2016-02-26 2017-08-31 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
WO2018139527A1 (ja) 2017-01-26 2018-08-02 小野薬品工業株式会社 キノリン誘導体のエタンスルホン酸塩
WO2019039525A1 (ja) 2017-08-23 2019-02-28 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
SG11202001664VA (en) * 2017-08-31 2020-03-30 Abbvie Inc Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
IL273579B2 (en) 2017-09-27 2025-10-01 Incyte Corp Salts of pyrrolizidine derivatives used as Tm inhibitors.
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
HRP20250676T1 (hr) 2018-06-29 2025-08-01 Incyte Corporation Formulacije inhibitora axl/mer
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
AU2021268210A1 (en) * 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
EP1153920B1 (en) * 1999-01-22 2003-10-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU2003280599A1 (en) * 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
ES2436888T3 (es) * 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US20100234371A1 (en) * 2005-08-22 2010-09-16 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
PL2101759T3 (pl) * 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK

Also Published As

Publication number Publication date
JP5746015B2 (ja) 2015-07-08
KR101325237B1 (ko) 2013-11-04
MX2010011224A (es) 2011-02-25
KR20100132038A (ko) 2010-12-16
JP2011517689A (ja) 2011-06-16
US9206130B2 (en) 2015-12-08
EP2262772B8 (en) 2013-03-13
RU2010146474A (ru) 2012-05-27
IL208103A0 (en) 2010-12-30
US20110092503A1 (en) 2011-04-21
AU2009237938A1 (en) 2009-10-22
WO2009127417A1 (en) 2009-10-22
IL208103A (en) 2015-08-31
ES2391373T3 (es) 2012-11-23
EP2262772A1 (en) 2010-12-22
CN102131783A (zh) 2011-07-20
EP2262772B1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
EP2262772B1 (en) Quinoline derivatives as axl kinase inhibitors
EP1415987B1 (en) Nitrogenous aromatic ring compounds as anti cancer agents
ES2868355T3 (es) Inhibidores del bromodominio
TWI473792B (zh) New quinoline compounds and their use
CA2909310A1 (en) Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
CN107098846B (zh) N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
WO2018145621A1 (zh) 喹啉类化合物、其制备方法及其医药用途
WO2015188747A1 (zh) 作为egfr抑制剂的苯基取代的三嗪类化合物及其应用
CN106478606B (zh) N-取代吲哚类衍生物及其应用
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
WO2017005137A1 (zh) 喹唑啉类化合物、其中间体、制备方法、药物组合物和应用
CN107056755B (zh) 五元杂环酰胺类wnt通路抑制剂
CA2603125A1 (en) Thienopyridine derivative, quinoline derivatives,and quinazoline derivatives, having c-met autophosphorylation inhibiting activity
ES2334708T3 (es) (3,4-dihidro-quinazolin-2-il)-(2-ariloxi-etil)-aminas que tienen una actividad sobre el receptor 5-ht.
BRPI0812816B1 (pt) Compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos
TW201934547A (zh) 一種嘧啶類化合物、其製備方法及其醫藥用途
WO2023061051A1 (zh) 一种磺酰胺类usp8抑制剂及其应用
CN102558144A (zh) 一种芳基脲衍生物
HK1156952A (en) Quinoline derivatives as axl kinase inhibitors
CN102408417B (zh) 2-取代乙烯磺酸酯类化合物及其制备方法和应用
WO2015043487A1 (zh) 喹唑啉类化合物及其制备方法与应用
CN104177312B (zh) 一种含硒化合物及其医药用途
CN105263926B (zh) 苯并噻吩化合物
CN117343046A (zh) 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
WO2025067486A1 (zh) 一类喹啉酮化合物、其制备方法和用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130416